GRI Bio, Inc. (GRI)
1.93
+0.09
(+4.89%)
USD |
NASDAQ |
Sep 18, 16:00
1.90
-0.03
(-1.55%)
After-Hours: 20:00
GRI Bio Net Income (Quarterly) : -1.643M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.643M |
| March 31, 2026 | -1.998M |
| December 31, 2025 | -2.659M |
| September 30, 2025 | -3.359M |
| June 30, 2025 | -2.892M |
| March 31, 2025 | -3.046M |
| December 31, 2024 | -1.948M |
| September 30, 2024 | -2.123M |
| June 30, 2024 | -2.25M |
| March 31, 2024 | -1.887M |
| December 31, 2023 | -2.004M |
| September 30, 2023 | -2.137M |
| June 30, 2023 | -6.746M |
| March 31, 2023 | -2.15M |
| December 31, 2022 | -2.269M |
| Date | Value |
|---|---|
| September 30, 2022 | -0.351M |
| June 30, 2022 | -0.295M |
| March 31, 2022 | -2.635M |
| December 31, 2021 | -3.096M |
| September 30, 2021 | -1.257M |
| June 30, 2021 | -2.312M |
| March 31, 2021 | -2.638M |
| December 31, 2020 | -1.469M |
| September 30, 2020 | -1.045M |
| June 30, 2020 | -1.147M |
| March 31, 2020 | -1.161M |
| December 31, 2019 | -0.8715M |
| September 30, 2019 | -0.949M |
| June 30, 2019 | -0.966M |
| March 31, 2019 | -0.678M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.643M |
| EPS Diluted (Quarterly) | -0.9103 |
| Enterprise Value | -6.684M |
| Earnings Yield | -2.27K% |
| Normalized Earnings Yield | -2266.33 |